Last update 05 Dec 2024

RiMO-301

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
RIMO 301
Target
IDO1
Mechanism
IDO1 inhibitors(Indoleamine 2,3-dioxygenase inhibitors)
Therapeutic Areas
Neoplasms
Active Indication
Head and neck cancer metastaticHead and Neck NeoplasmsAdvanced cancer
Inactive Indication
Prostatic Cancer
Originator Organization
RiMO Therapeutics LLCRiMO Therapeutics LLC
Active Organization
University of IllinoisUniversity of IllinoisCoordination Pharmaceuticals, Inc.Coordination Pharmaceuticals, Inc.Startup
Inactive Organization
RiMO Therapeutics LLCRiMO Therapeutics LLC
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with RiMO-301
NCT05838729 / RecruitingPhase 1/2
Phase 1b/2a Study of RiMO-301 and Hypofractionated Radiotherapy With A PD-1 Inhibitor for the Treatment of Unresectable, Recurrent or Metastatic Head-Neck Cancer
NCT03444714 / RecruitingPhase 1
Phase I Dose-Escalating Study of RiMO-301 With Radiation in Advanced Tumors
100 Clinical Results associated with RiMO-301
Login to view more data
100 Translational Medicine associated with RiMO-301
Login to view more data
100 Patents (Medical) associated with RiMO-301
Login to view more data
100 Deals associated with RiMO-301
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Head and neck cancer metastaticPhase 2
US
University of IllinoisUniversity of Illinois
03 Apr 2023
Head and neck cancer metastaticPhase 2
US
Coordination Pharmaceuticals, Inc.Coordination Pharmaceuticals, Inc.Startup
03 Apr 2023
Head and Neck NeoplasmsPhase 2
US
University of IllinoisUniversity of Illinois
03 Apr 2023
Head and Neck NeoplasmsPhase 2
US
Coordination Pharmaceuticals, Inc.Coordination Pharmaceuticals, Inc.Startup
03 Apr 2023
Prostatic CancerPhase 1
US
RiMO Therapeutics LLCRiMO Therapeutics LLC
26 Jun 2018
Advanced cancerPhase 1
US
Coordination Pharmaceuticals, Inc.Coordination Pharmaceuticals, Inc.Startup
10 Apr 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT03444714 (ASCO2023)
ManualManual
Phase 1
Neoplasms
25
trhuzqwfdr(rowjqfknjj) = No protocol defined DLT was reported. khubbdolkr (zhbhfyuvgu )
View more
Positive
31 May 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free